Plasminogen activator inhibitor-1 (PAI-1) like the best mortality predictor of in the COVID-19-associated pneumonia

ABSTRACT

The aim was to estimate the prognostic role of PAI-1 on admission in hospitalized patients with confirmed COVID-19 pneumonia. Material(s) and Method(s) We observed 2 groups Main - 85 patients (59 (52;65) years, men - 45 (52.9%)), hospitalized with COVID-19 pneumonia;Control - 25 healthy volunteers (50.0 (35;65) years, men - 13 (52.0%)). General tests, PAI-1 (ELISA Kit, Elabscience) before anticoagulants, autopsy data, statistic. Result(s) At admission the level of PAI-1 in Main group was in 60 times higher than in Control group (6.1 [0.15;18] ng/ml versus 0.1 [0.09;0.11] ng/ml, p=0,000). Despite the adequate treatment 12 patients died from COOVID-19 pneumonia. Maximal levels of PAI-1 were in died patients. ROC analysis shows the powerful reliable connection between increased level of PAI-1 higher than 20,6 ng/ml at admission and COVID-19 mortality (OR=219;CI=95% (7,7056 to 6224,1404);p=0,0016). Conclusion(s) 1) problem in fibrinolysis plays the crucial role in thrombogenesis in COVID-19;2) increased PAI-1 more than 20 ng/l is associated with 200-times higher risk of mortality. (Figure Presented).